This phase III clinical trial is designed to evaluate the efficacy and safety of autologous Mesenchymal Stem Cells (MSC) injected hepatic artery.
At the time of screening, 19 or 70 years
Patients diagnosed with alcoholic cirrhosis by combining alcohol history, imaging and pathological examination results, and clinical symptoms at screening, and belonging to Child-Pugh grade B or C (Child-Pugh score of 7 or more)
Those whose survival period is more than 1 year when judged by the tester
Those who can perform hepatic artery catheterization by inserting a catheter into the hepatic artery at the judgment of the examiner
Those with a history of solid cancer including Hepatocellular Carcinoma (HCC) (within 5 years before screening), those who have been diagnosed with solid cancer and are currently undergoing chemotherapy or those whose hepatocellular carcinoma has been confirmed by screening tests
Patients who underwent portal systemic shunting in the jugular vein
Patients with alcohol consumption or hepatotoxic drugs within 6 months prior to screening
Persons taking high-dose steroids, immunosuppressants, or antimicrobials due to severe infections for at least 1 month of screening